<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04082910</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-PLAGH-BT-044</org_study_id>
    <nct_id>NCT04082910</nct_id>
  </id_info>
  <brief_title>Metoprolol for the Treatment of Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells</brief_title>
  <official_title>Metoprolol for the Treatment of Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this single-center prospective study is to evaluate the efficacy and feasibility
      of Metoprolol, a beta-blocker, in the treatment of cytokine release syndrome (CRS) caused by
      Chimeric antigen receptor T (CART) cells, to verify its effects on decreasing the level of
      Interleukin-6 (IL-6), and to determine whether it can replace the intervention of other
      antibodies, such as tocilizumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Metoprolol on CRS</measure>
    <time_frame>two weeks</time_frame>
    <description>Control of CRS, based on the change of temperature</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of IL-6 after Metoprolol</measure>
    <time_frame>two weeks</time_frame>
    <description>Detection of the level of IL-6 in Peripheral blood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Hematologial Malignancy</condition>
  <arm_group>
    <arm_group_label>Therapeutic group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with predicted experiencing ≤ grade 2 CRS after CAR T cells infusion, will be enrolled therapeutic group (metoprolol monotherapy, 12.5mg per time, bid; from the peak phase to extinction phase of CRS, up to 7 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prophylactic group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with predicted experiencing ≥ grade 3 CRS after CAR T cells infusion, will be enrolled prophylactic group (metoprolol plus anti-TNFα antibody. 1) metoprolol, 12.5mg per time, bid; from one day before cells infusion to extinction phase of CRS, up to 14 days. 2) anti-TNFα antibody will be used at the peak period of CRS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Metoprolol for patients undergoing CRS after CAR T cells infusion.</description>
    <arm_group_label>Prophylactic group</arm_group_label>
    <arm_group_label>Therapeutic group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-TNFα antibody</intervention_name>
    <description>Metoprolol plus anti-TNFα antibody for patients in prophylactic group.</description>
    <arm_group_label>Prophylactic group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female participant 18 Years to 70 Years Patients with malignant tumors who
             received the treatment of CART cells. Estimated life expectancy ≥ 12 weeks (according
             to investigator's judgement) Eastern Cooperative Oncology Group (ECOG) performance
             status ≤ 2 Adequate organ function

        Exclusion Criteria:

          -  Significant bradycardia (heart rate &lt; 45/min) cardiogenic shock severe or acute heart
             failure poor peripheral circulation perfusion degree II or III atrioventricular block
             sick sinus syndrome severe peripheral vascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weidong Han, M.D.</last_name>
    <phone>+861055499341</phone>
    <email>hanwdrsw@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biotherapeutic Department of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong Han, M.D</last_name>
      <phone>+861055499341</phone>
      <email>hanwdrsw@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Qingming Yang, M.D</last_name>
      <phone>+861055499341</phone>
      <email>yangqm@medmail.com.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Han weidong</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Metoprolol</keyword>
  <keyword>cytokine release syndrome</keyword>
  <keyword>chimeric antigen receptor T cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

